<code id='A58DB49580'></code><style id='A58DB49580'></style>
    • <acronym id='A58DB49580'></acronym>
      <center id='A58DB49580'><center id='A58DB49580'><tfoot id='A58DB49580'></tfoot></center><abbr id='A58DB49580'><dir id='A58DB49580'><tfoot id='A58DB49580'></tfoot><noframes id='A58DB49580'>

    • <optgroup id='A58DB49580'><strike id='A58DB49580'><sup id='A58DB49580'></sup></strike><code id='A58DB49580'></code></optgroup>
        1. <b id='A58DB49580'><label id='A58DB49580'><select id='A58DB49580'><dt id='A58DB49580'><span id='A58DB49580'></span></dt></select></label></b><u id='A58DB49580'></u>
          <i id='A58DB49580'><strike id='A58DB49580'><tt id='A58DB49580'><pre id='A58DB49580'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:14716
          Cambridge: AbbVie
          The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 — nearly a million dollars more than the company has ever spent in a single quarter. Ruby Wallau for STAT

          WASHINGTON — The pharma giant AbbVie spent nearly $4 million on lobbying in the first three months of 2022 alone — more than any other drugmaker spent in the same period, and nearly a million dollars more than the company spent in the same period last year.

          AbbVie was the seventh-highest corporate lobbying spender last quarter, ahead of giants like Lockheed Martin, CVS Health, and, AT&T, federal records show.

          advertisement

          The number is eye-popping even for the pharmaceutical industry, which is known for its omnipresence on Capitol Hill, and its nearly unlimited lobbying budgets.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal
          Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Study: Pain burden is higher in Black NFL players than white ones

          JuliusThomas,nowpursuinghisPh.D.inpsychology,playingfortheMiamiDolphinsin2017.AdrianKraus/APIt’stobe